DK1635838T3 - Phosphodiesterase 5 inhibitorer til profylakse og/eller behandling af portal hypertension - Google Patents
Phosphodiesterase 5 inhibitorer til profylakse og/eller behandling af portal hypertensionInfo
- Publication number
- DK1635838T3 DK1635838T3 DK04739573T DK04739573T DK1635838T3 DK 1635838 T3 DK1635838 T3 DK 1635838T3 DK 04739573 T DK04739573 T DK 04739573T DK 04739573 T DK04739573 T DK 04739573T DK 1635838 T3 DK1635838 T3 DK 1635838T3
- Authority
- DK
- Denmark
- Prior art keywords
- portal hypertension
- portal
- inhibitor
- prevent
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10325813A DE10325813B4 (de) | 2003-06-06 | 2003-06-06 | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
PCT/EP2004/006014 WO2004108062A2 (de) | 2003-06-06 | 2004-06-03 | Prophylaxe und/oder therapie bei der portalen hypertonie |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1635838T3 true DK1635838T3 (da) | 2007-09-10 |
Family
ID=33494881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04739573T DK1635838T3 (da) | 2003-06-06 | 2004-06-03 | Phosphodiesterase 5 inhibitorer til profylakse og/eller behandling af portal hypertension |
DK06025229.3T DK1923073T3 (da) | 2003-06-06 | 2004-06-03 | Kombinationsmedicin med PDE-5-inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06025229.3T DK1923073T3 (da) | 2003-06-06 | 2004-06-03 | Kombinationsmedicin med PDE-5-inhibitor |
Country Status (14)
Country | Link |
---|---|
US (1) | US9278097B2 (da) |
EP (2) | EP1923073B1 (da) |
JP (3) | JP4557970B2 (da) |
KR (2) | KR101233828B1 (da) |
CN (1) | CN1871010B (da) |
AT (2) | ATE361074T1 (da) |
CY (2) | CY1107707T1 (da) |
DE (2) | DE10325813B4 (da) |
DK (2) | DK1635838T3 (da) |
ES (2) | ES2287740T3 (da) |
PL (2) | PL1635838T3 (da) |
PT (2) | PT1635838E (da) |
SI (2) | SI1635838T1 (da) |
WO (1) | WO2004108062A2 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL363679A1 (en) * | 2001-05-09 | 2004-11-29 | Bayer Healthcare Ag | Novel use of 2-phenyl-substituted imidazotriazinones |
DE10232113A1 (de) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
JP4879977B2 (ja) * | 2005-06-10 | 2012-02-22 | ドン・ア・ファーム・カンパニー・リミテッド | ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤 |
BRPI0616633A2 (pt) * | 2005-09-29 | 2011-06-28 | Bayer Healthcare Ag | inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos |
US8512258B2 (en) * | 2005-11-11 | 2013-08-20 | Exalenz Bioscience Ltd. | Breath test device and method |
JP2010532319A (ja) * | 2007-06-13 | 2010-10-07 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のpde阻害剤 |
WO2014088326A1 (ko) | 2012-12-04 | 2014-06-12 | 주식회사 아리바이오 | 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물 |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
US11576609B2 (en) | 2017-06-30 | 2023-02-14 | Georgia State University Research Foundation, Inc. | Noninvasive methods for detecting liver fibrosis |
CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
CN110811593A (zh) * | 2019-11-07 | 2020-02-21 | 天津中医药大学第二附属医院 | 一种高血压中医证型采取肝血流动力学特点的判别方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2882843B2 (ja) | 1990-03-28 | 1999-04-12 | 日本化薬株式会社 | 門脈圧亢進症改善剤 |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
US5973011A (en) * | 1994-03-30 | 1999-10-26 | Isis Pharma Gmbh | Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction |
DE19961302A1 (de) * | 1999-12-18 | 2001-06-21 | Dresden Arzneimittel | Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen |
KR20010101603A (ko) | 1999-01-20 | 2001-11-14 | 노왈드 | 이미다조[1,5-a]-피리도[3,2-e]-피라지논의 약제로서의용도 |
AU3210500A (en) | 1999-01-22 | 2000-08-07 | Selectus Pharmaceuticals, Inc. | Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence |
US6087362A (en) | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US20010003120A1 (en) * | 1999-05-14 | 2001-06-07 | M. D. Robert Hines | Method for treating erectile dysfunction |
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
US20020103117A1 (en) * | 2000-02-03 | 2002-08-01 | Ralph Knoell | Use of protein kinase-inhibitor-alpha |
DE10004858A1 (de) | 2000-02-03 | 2001-08-16 | Schering Ag | Verwendung von Proteinkinase-Inhibitor-alpha |
US6476037B1 (en) * | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
EP1313478A2 (en) | 2000-08-30 | 2003-05-28 | Lilly Icos LLC | Method for treatment of migraine using pde5 inhibitors |
US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
JP2002201128A (ja) | 2000-10-25 | 2002-07-16 | Takeda Chem Ind Ltd | 門脈圧亢進症予防・治療剤 |
US20040102502A1 (en) * | 2000-10-25 | 2004-05-27 | Toshifumi Watanabe | Preventing/remedies for portal hypertension |
CN1499969A (zh) * | 2001-01-31 | 2004-05-26 | Ĭ��ר���ɷ�����˾ | 含有吡唑并[4,3-d]嘧啶和硝酸酯或噻吩并嘧啶和硝酸酯的药物组合物 |
BR0206847A (pt) * | 2001-02-02 | 2004-02-25 | Pfizer | Tratamento do diabete melito |
CN1489467A (zh) | 2001-02-02 | 2004-04-14 | Ĭ��ר���ɷ�����˾ | 含吡唑并[4,3-d]嘧啶和内皮素受体拮抗剂或者噻吩并嘧啶和内皮素受体拮抗剂的药物制剂 |
US6338862B1 (en) * | 2001-03-26 | 2002-01-15 | Sarfaraz K Niazi | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
NZ530007A (en) | 2001-06-08 | 2006-02-24 | Sod Conseils Rech Applic | Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity |
LV12979B (en) | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
-
2003
- 2003-06-06 DE DE10325813A patent/DE10325813B4/de not_active Expired - Fee Related
-
2004
- 2004-06-03 EP EP06025229A patent/EP1923073B1/de not_active Expired - Lifetime
- 2004-06-03 DK DK04739573T patent/DK1635838T3/da active
- 2004-06-03 JP JP2006508268A patent/JP4557970B2/ja not_active Expired - Fee Related
- 2004-06-03 DE DE502004003694T patent/DE502004003694D1/de not_active Expired - Lifetime
- 2004-06-03 EP EP04739573A patent/EP1635838B1/de not_active Expired - Lifetime
- 2004-06-03 PL PL04739573T patent/PL1635838T3/pl unknown
- 2004-06-03 AT AT04739573T patent/ATE361074T1/de active
- 2004-06-03 WO PCT/EP2004/006014 patent/WO2004108062A2/de active IP Right Grant
- 2004-06-03 KR KR1020117030506A patent/KR101233828B1/ko not_active IP Right Cessation
- 2004-06-03 DK DK06025229.3T patent/DK1923073T3/da active
- 2004-06-03 PT PT04739573T patent/PT1635838E/pt unknown
- 2004-06-03 SI SI200430378T patent/SI1635838T1/sl unknown
- 2004-06-03 ES ES04739573T patent/ES2287740T3/es not_active Expired - Lifetime
- 2004-06-03 PT PT06025229T patent/PT1923073E/pt unknown
- 2004-06-03 ES ES06025229T patent/ES2374085T3/es not_active Expired - Lifetime
- 2004-06-03 AT AT06025229T patent/ATE525074T1/de active
- 2004-06-03 SI SI200431750T patent/SI1923073T1/sl unknown
- 2004-06-03 PL PL06025229T patent/PL1923073T3/pl unknown
- 2004-06-03 US US10/559,694 patent/US9278097B2/en not_active Expired - Fee Related
- 2004-06-03 CN CN2004800225122A patent/CN1871010B/zh not_active Expired - Fee Related
-
2005
- 2005-12-05 KR KR1020057023300A patent/KR101176110B1/ko not_active IP Right Cessation
-
2007
- 2007-08-01 CY CY20071101024T patent/CY1107707T1/el unknown
-
2009
- 2009-07-24 JP JP2009172766A patent/JP5757677B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-12 JP JP2010109855A patent/JP5631053B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-07 CY CY20111100960T patent/CY1111918T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107707T1 (el) | Αναστολεις της φωσφοδιεστερασης-5 για την προφυλαξη και/ή τη θεραπεια της πυλαιας υπερτασης | |
BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
NO20082790L (no) | Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion | |
ATE534404T1 (de) | Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe | |
BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
ATE409466T1 (de) | Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen | |
NO20060416L (no) | Ny anvendelse I | |
RU2007121737A (ru) | Лечение аденомы и/или аденокарциномы кишечника с помощью ингибирования активации пути notch | |
NO20053041L (no) | Behandling av diabetes. | |
NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
DE602007008385D1 (de) | Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris | |
PT942751E (pt) | Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores | |
WO2005097103A3 (en) | Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors | |
NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
DK1469859T3 (da) | Anvendelse af flerumættede ketoner til behandling af psoriasis | |
DE60116642D1 (de) | Verbindungen mit cytochrom p450ra1 hemmenden aktivität | |
DE60234246D1 (de) | Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen | |
NO980221L (no) | Fremgangsmåte for behandling av tykktarmsadenomer | |
WO2007117981A3 (en) | Selective hydroxamate based mmp inhibitors | |
NO20026251L (no) | Ventilanordning med middels bruddtrykk | |
NO20051390L (no) | Fremgangsmate for behandling av pasienter med massivt blodtap | |
EA200700406A1 (ru) | Производные хиназолина , применяемые для лечения поражений периферических артерий и в качестве ингибиторов фосфодиэстеразы | |
BR0015039A (pt) | Método para administrar um inibidor fosfodiesterase 4 | |
DK1865990T3 (da) | Fremgangsmåde til behandling af type 2 diabetes |